about
A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line.Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic.Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks.Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy.Cancer stem cells: the development of new cancer therapeutics.Mitochondrial proteomic approaches for new potential diagnostic and prognostic biomarkers in cancer.Towards the standardization of mitochondrial proteomics: the Italian mt-HPP initiative.The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects.CA 19-9: Biochemical and Clinical Aspects.A Critical Approach to Clinical Biochemistry of Chromogranin A.The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research.Cryoglobulin Test and Cryoglobulinemia Hepatitis C-Virus Related.Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer.Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition.Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
P50
Q33425048-62D04FFF-9215-4076-A20C-9E1ED60A9D0FQ34045300-35996D0C-6872-4DAF-8F50-4873BF3AAAD3Q36809514-8F093A6B-55E8-4F4C-8E59-4B1D7F27EFD5Q37639400-0ED0B558-1192-4DAB-B212-9605585C3EA5Q37817278-E3BC3036-7B76-403A-90F6-04B7406098E5Q37861207-649E499C-0E22-4A56-9FE7-C8A056CFB53EQ37991647-BAE4AD68-02C5-40D0-9696-5BD5D65EFF30Q38371839-644335F9-EAA1-486F-A64A-C9D3135C709FQ38623675-47786944-7D8E-4608-94A6-5494764A342FQ38623677-6AA61010-8403-47A0-81A1-45AA64240AFCQ38623689-C72FC91F-9C82-4537-9FE5-6822A3657DAEQ38633203-EF14715A-E3AD-4F83-A63A-10E6902CC4C2Q39094313-FD49245B-3B4D-48C2-A793-18E924A4ED60Q40019001-F4715161-523E-44BA-8F3A-B64DD868BEDBQ40246576-34F73F80-69E6-4E6B-BD3B-FDAB3E047201Q40281693-E8325E31-E557-4FA5-9C55-6283A255B312Q40530654-5CF54224-A948-4011-8EE2-DFFA7435B03FQ40582883-10773F56-F9A0-4FE4-AE22-E86D24E2A598Q42810139-E7ADE568-C9E0-4BC9-A551-8C1813F4FBDB
P50
description
researcher ORCID ID = 0000-0001-5427-8903
@en
wetenschapper
@nl
name
Patrizia Bottoni
@ast
Patrizia Bottoni
@en
Patrizia Bottoni
@es
Patrizia Bottoni
@nl
type
label
Patrizia Bottoni
@ast
Patrizia Bottoni
@en
Patrizia Bottoni
@es
Patrizia Bottoni
@nl
prefLabel
Patrizia Bottoni
@ast
Patrizia Bottoni
@en
Patrizia Bottoni
@es
Patrizia Bottoni
@nl
P106
P1153
7006566344
P21
P31
P496
0000-0001-5427-8903